New topics in the ACCP guideline include the perioperative management of patients receiving direct oral anticoagulants and P2Y12 inhibitor antiplatelet drugs.
Researchers sought to determine whether direct oral anticoagulant or warfarin would be better for recurrent VTE in patients taking extended anticoagulation treatment.
A study was conducted to assess clinical outcomes via 90-day home time in patients with medium-vessel occlusion treated with endovascular thrombectomy.
Researchers sought to determine whether lowering apixaban from the standard 5.0 mg twice daily dose to 2.5 mg twice daily would impact bleeding and thrombosis rates for patients with cancer.
Researchers sought to determine whether recombinant ADAMTS13 prophylaxis would be a viable therapy for patients with congenital thrombotic thrombocytopenic purpura.
Researchers sought to determine whether LMWH would lead to a reduction in the likelihood of developing a symptomatic confirmed VTE in hospitalized patients.
Researchers sought to determine whether LMW heparin would increase the rate of live births seen in women with inherited thrombophilia and recurrent miscarriage.
Researchers sought to determine whether early administration of 4F-PCC would reduce 24-hour blood product consumption in patients with trauma at risk of massive transfusion.
Researchers quantified the risks of bleeding and VTE associated with early VTE prophylaxis in critically ill patients with thrombocytopenia in a range of platelet counts.
Researchers sought to determine whether anticoagulation therapy using rivaroxaban would be effective in children with cancer-associated venous thromboembolism.
Researchers conducted an analysis of the Gab2-MALT1 pathway to determine whether it impacts the development of thromboinflammation and deep vein thrombosis.
Researchers explored the use of D-dimer levels to rule out PTE in patients with COVID-19, as well as clinical associations between D-dimer levels and PTE.
Researchers assessed the 30-day risk for VTE among ambulatory patients with COVID-19 and compared, via propensity-score matching, individuals without COVID-19 infection.
Researchers assessed the relationship between oral anticoagulation for patients with COVID-19 and AF and incidence of in-hospital thrombotic events and death.
Can the pulmonary embolism severity index assess the risk for adverse events among patients hospitalized for COVID-19 who are not diagnosed with PE or VTE?